 A Message From Profits Run If you still haven't downloaded my "Safe Trade Options Formula" book... ...please take a few seconds and download it right now before your new temporary download link expires. I eventually plan to charge for this book, so do yourself a favor and download it now... That way, no matter how much it is in the future, you'll have a copy on your computer already. Make sense? FREE: Safe Trade Options Formula << Download Now Good Trading,
Bill Poulos p.s. Go here to save a copy of my "Safe Trade Options Formula" book to your computer before I start charging for it.
This Week's Exclusive News
Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AIAuthored by Bridget Bennett. Date Posted: 10/8/2026. 
Key Points
- Whitney Tilson argues record index highs mask a broad bear market, since 19 of the top 20 S&P 500 contributors are AI-related while most stocks lag.
- Tilson favors three non-AI value picks: speculative Joby Aviation, undervalued Casey's General Stores, and underappreciated Eli Lilly, each hit by sentiment rather than fundamentals.
- Each stock has a specific catalyst to watch: Joby's first commercial flight, Casey's in-store same-store sales, and Eli Lilly's retatrutide FDA filing.
- Special Report: Your 401k Stocks Could Soon Become Digital Tokens
The market has hit a record high, and almost none of that gain belongs to the average stock. That gap is where Whitney Tilson of Stansberry Research is doing his shopping. His case is that the index is masking a broad bear market underneath and that the clearest values right now sit entirely outside artificial intelligence. Three names make the case: a speculation, an off-the-radar mid-cap and the world's largest drugmaker. A Record-High Index Is Masking a Market-Wide Bear Market
By Tilson's count, 19 of the 20 largest contributors to the S&P 500 this year are AI-related, and those names account for essentially the entire 13% index return. The other 480 stocks are collectively flat. Roughly 59% of S&P 500 components trade at least 20% below their all-time highs, and about one in six is down 50% or more. That is what a bifurcated market looks like, and it is why a value investor staring at a 99th-percentile Shiller multiple still has a long shopping list. Tilson follows the old Buffett-Munger approach: estimate what a private buyer would pay for the whole business, then buy at a steep discount. The strategy requires the market to make mistakes, and a market this narrow makes plenty. ServiceNow (NYSE: NOW) was a recent example. Investors priced in agentic AI gutting enterprise software subscriptions, while large corporations declined to rip out systems that worked, and the stock recovered sharply. Joby Aviation Is a Speculation With a Second Buyer AttachedJoby Aviation (NYSE: JOBY) builds an electric aircraft that takes off vertically, then rotates its motors forward to fly. It behaves like a helicopter and runs roughly 99% quieter, which is the entire commercial argument: Most helicopters are not welcome over cities. Tilson first recommended the stock near $7 three years ago. It tripled, then round-tripped back to about $7 and a $6 billion market cap. The caveats are significant: no revenue, no FAA approval and no commercial flights. This is a position to size carefully, not a core holding. The market is pricing in a delay. Commercial service in the United Arab Emirates, including a 30-minute hop between Abu Dhabi and Dubai, was pushed back when regional conflict interrupted the timeline, and investors who saw no near-term catalyst sold. U.S. approval is realistically one to two years away, though Joby sits further along than any competitor. What could change sentiment is the first paying flight. What limits the downside is everything else the company owns: electric motor and battery technology, an engineering team and aircraft already delivered to the U.S. Air Force, where a silent airframe has obvious value. If air taxis never become a business, Tilson expects a bidding war from electric vehicle makers and defense contractors. Casey's General Stores Looks Like Walmart Did in 1988Casey's General Stores (NASDAQ: CASY) operates about 3,000 convenience stores across 19 states from its Des Moines headquarters, generating roughly $18 billion in revenue against a $22 billion market cap. It is the third-largest convenience chain in the United States and the fifth-largest seller of pizza, which is the point: The high-margin in-store business carries the model, and more than half of sales now run through the app. The stock fell about 34% in two months, dropping its valuation from 35 times forward earnings to 26 times. The trigger was a quarter in which fuel margins drove the earnings beat while in-store comparable sales decelerated and management reaffirmed rather than raised guidance. At a premium multiple, reaffirming is not enough. Nothing about the competitive position changed. Walmart (NYSE: WMT) generated the same $18.6 billion in trailing sales in mid-1988, with nearly identical profitability and an almost identical forward multiple, and its stock has since become close to a 100-bagger. The comparison is not a forecast. It is a reminder that 26 times earnings is cheap for a business that can compound earnings at a double-digit rate for a decade. Casey's targets towns of 500 to 20,000 people, and Texas alone has roughly 2,000 of them. Eli Lilly's Next Obesity Drug Is the Part the Market Is DiscountingEli Lilly (NYSE: LLY) carries a trillion-dollar market cap and trades near 40 times trailing earnings, which makes it look like a story investors have already missed. Tilson puts the company in the middle innings at most. Two factors support that view. The first is retatrutide, Lilly's next-generation weight-loss candidate and the first to target three hormone receptors at once, rather than the two targeted by tirzepatide in Zepbound and Mounjaro. Average weight loss in trials has been closer to 29%, compared with roughly 20% on Zepbound, with less muscle loss. Lilly plans to file with the FDA in early 2027, which puts a launch in late 2027 at the earliest. The second is the size of the eventual market. Studies continue to surface potential benefits beyond weight loss, including improvements in fatty liver disease, sleep apnea, inflammation, cholesterol and addictive behavior. The argument is that demand eventually extends beyond people who need to lose weight, with low-dose use becoming common among those who do not. Based on estimates Tilson believes are too conservative, Lilly trades near 28 times forward earnings, below where it has traded for most of the past few years. Where the Risk and the Upside SitThe risks are uneven. Joby can drift for quarters without a catalyst and burn investor goodwill along the way. Casey's needs in-store comparable sales to stabilize, because a fuel-led beat leaves guidance looking fragile. Lilly faces real pricing pressure across the category and a long regulatory runway before retatrutide sells a single dose. The upside shares one trait: All three stocks sold off on sentiment rather than broken fundamentals, which is the only condition under which a value approach works at all. Watch the catalysts instead of the quotes: Joby's first commercial flights, Casey's in-store same-store sales and Lilly's retatrutide filing. Those are the events most likely to move these three stocks. For investors looking for more of Tilson's insights, visit here. . |
